| ²é¿´: 1350 | »Ø¸´: 2 | ||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷Õßwfpzmd360073½«ÔùËÍÄú 30 ¸ö½ð±Ò | ||
wfpzmd360073½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÎÄÏ×ÇóÖú£¬¼±¼±¼±£¡£¡£¡£¡ ÒÑÓÐ1È˲ÎÓë
|
|
|
ÇóÖúһƪÁÙ´²Ñо¿ÎÄÕ£¬Â·¹ýµÄ´óÉñÇë°ï棬лл£¡£¡£¡£¡ Á´½Ó£ºhttps://pubmed.ncbi.nlm.nih.gov/38823410/ doi: 10.1016/S1470-2045(24)00159-1. Epub 2024 May 29 ÌâÄ¿£ºBL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study |
» ²ÂÄãϲ»¶
±±¾©ÐºÍҽѧԺ½ÜÇà¿ÎÌâ×éÕÐÆ¸¿ÆÑÐÖúÀí
ÒѾÓÐ0È˻ظ´
ÇóÖúÖйúÒ©µä1995Äê°æ¡¢¶þ²¿
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ190È˻ظ´
ÔÚÏßÇóÖú£¬¼±£¡£¡£¡ÇëÎÊÄÄÀï¿ÉÒÔ×ö´ÅÐÔÄÉÃײÄÁϵĸ߷ֱæÍ¸Éäµç¾µµÄ²âÊÔ±íÕ÷ѽ£¿
ÒѾÓÐ5È˻ظ´
±±¾©ÐºÍҽѧԺ½ÜÇà¿ÎÌâ×éÕÐÆ¸¿ÆÑÐÖúÀí
ÒѾÓÐ0È˻ظ´
¸£ÖÝ´óѧÀîÐËÊç½ÌÊÚ¿ÎÌâ×é¼±Õв©Ê¿Ñо¿Éú
ÒѾÓÐ9È˻ظ´
Liquid Chromatography-Mass Spectrometry Analysis of Small Interfering RNAs
ÒѾÓÐ1È˻ظ´
ÇóÖúhttps://www.pnas.org/doi/10.1073/pnas.2535777123 È«ÎÄ
ÒѾÓÐ0È˻ظ´
¼Ó°ÍÅç¶¡½ºÄÒ¼¤ËØ6Ô³¬ÏÞÔÓÖʽṹ
ÒѾÓÐ4È˻ظ´
ÖÐÒ©¼ì²âÖÖ¾öÃ÷×Ó¡¢è×ʵ¡¢Ë®òΡ¢ÜòÜ߯·ÖÖ¼ì²âÎÊÌâ½»Á÷
ÒѾÓÐ1È˻ظ´

zyqchem
ľ³æÖ®Íõ (ÎÄѧ̩¶·)
- Ó¦Öú: 161 (¸ßÖÐÉú)
- ½ð±Ò: 295698
- ºì»¨: 566
- ɳ·¢: 1982
- Ìû×Ó: 56484
- ÔÚÏß: 12237Сʱ
- ³æºÅ: 3786654
- ×¢²á: 2015-04-04
- רҵ: ºÏ³ÉÒ©Îﻯѧ
2Â¥2025-11-26 12:01:26
tfang
ľ³æÖ®Íõ (ÎÄѧ̩¶·)
ľ³æ008Ö®´óÀÁ³æ
- Ó¦Öú: 185 (¸ßÖÐÉú)
- ¹ó±ö: 0.002
- ½ð±Ò: 173722
- É¢½ð: 8530
- ºì»¨: 217
- ɳ·¢: 4
- Ìû×Ó: 57198
- ÔÚÏß: 2595.8Сʱ
- ³æºÅ: 529162
- ×¢²á: 2008-03-20
- ÐÔ±ð: GG
- רҵ: ÂÌÉ«Óлú»¯Ñ§
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
|
ͨ¹ýÍøÅÌ·ÖÏíµÄÎļþ£ºBL-B01D1, a first-in-class EGFR¨CHER3 bispecific antibody¨Cdrug conjugate, in patients with locally advanced or metastatic solid tumours a first-in-human, open-label, multicentre, phase 1 study._20251127_083531.pdf Á´½Ó: https://pan.baidu.com/s/1Fjp97hdJLNbLM_NIE6nOHQ?pwd=bpib ÌáÈ¡Âë: bpib ¸´ÖÆÕâ¶ÎÄÚÈݺó´ò¿ª°Ù¶ÈÍøÅÌÊÖ»úApp£¬²Ù×÷¸ü·½±ãŶ |

3Â¥2025-11-27 08:35:43









»Ø¸´´ËÂ¥